Literature DB >> 20661822

Evaluation of MTHFR677C>T polymorphism in prediction and prognosis of esophageal squamous cell carcinoma: a case-control study in a northern Indian population.

Meenakshi Umar1, Rohit Upadhyay, Rohini Khurana, Shaleen Kumar, Uday Chand Ghoshal, Balraj Mittal.   

Abstract

Early diagnosis and better prognosis of esophageal squamous cell carcinoma (ESCC) is still a challenge. Besides environmental risk factors, nutritional deficiencies have an established role in pathogenesis of ESCC. Folate deficiency and functional polymorphisms in folate metabolizing genes such as methylene tetrahydrofolate reductase (MTHFR) 677C>T may have oncogenic role through disruption of normal DNA methylation pattern, synthesis, and impaired DNA repair. MTHFR677C>T or A222V (rs1801133) polymorphism has conflicting role in susceptibility to ESCC among different populations. Thus, we aimed to study the role of MTHFR677C>T polymorphism in susceptibility, survival, and interaction with environmental risk factors in ESCC patients from a northern Indian population. A case control study was performed in 208 ESCC incident cases (including 114 follow-up cases) and 223 healthy controls, and genotyping was done by PCR-RFLP. Our results show no significant association of MTHFR677C>T polymorphism with ESCC, tumor locations, or gender of subjects. However, we found a trend of decreased risk of ESCC due to interaction of MTHFR677CT genotype with smoking and alcohol intake. Kaplan Meier, and Cox regression survival analysis showed no prognostic impact of MTHFR677C>T polymorphism in ESCC patients. In conclusion, MTHFR677C>T polymorphism does not seem to have significant role either in susceptibility or survival of ESCC in a northern Indian population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661822     DOI: 10.1080/01635581003605961

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  8 in total

1.  Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India.

Authors:  Raju K Mandal; Kamran Nissar; Rama D Mittal
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

2.  Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Rohini Khurana; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

3.  PLCE1 rs2274223 A>G polymorphism and cancer risk: a meta-analysis.

Authors:  Meenakshi Umar; Rohit Upadhyay; Balraj Mittal
Journal:  Tumour Biol       Date:  2013-12

4.  Role of novel and GWAS originated PLCE1 genetic variants in susceptibility and prognosis of esophageal cancer patients in northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Tumour Biol       Date:  2014-08-21

Review 5.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

6.  The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and tumor risk: evidence from 134 case-control studies.

Authors:  Min Tang; Shang-Qian Wang; Bian-Jiang Liu; Qiang Cao; Bing-Jie Li; Peng-Chao Li; Yong-Fei Li; Chao Qin; Wei Zhang
Journal:  Mol Biol Rep       Date:  2014-04-18       Impact factor: 2.316

Review 7.  Methylenetetrahydrofolate reductase genetic polymorphisms and esophageal squamous cell carcinoma susceptibility: A meta-analysis of case-control studies.

Authors:  Yang Shujuan; Zhang Jianxing; Chen Xin-Yue
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

Review 8.  A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Authors:  J M Findlay; M R Middleton; I Tomlinson
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.